Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > Analysis

<< Previous

Bullboard Posts

Next >>

Comment by mercedesmanon Jun 08, 2024 4:33pm

130 Views

Post# 36079465

RE:RE:RE:RE:RE:Analysis

I think this is as simple as stringing together several more quarters of better than expected margins and profits to make everyone forget about fiscal 2023.

Getting annualized revenues above $30 M will help too.

Otherwise this gets taken out for a song ( but still at a premium) as K royalties get closer and closer to reality.

Investors today basically get huge Kinlytic upside for free .

MM

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario